Literature DB >> 23266258

Performance of the ViroSeq HIV-1 genotyping system v2.0 on HIV-1 strains circulating in Senegal.

Moussa Thiam1, Halimatou Diop-Ndiaye, Khady Kebe, Nicole Vidal, Rokhaya Diakhate-Lô, Abou Abdallah Malick Diouara, Nafissatou Leye, Ousseynou Ndiaye, Amina Sow, Ndeye Fatou Ngom-Gueye, Souleymane Mboup, Coumba Toure-Kane.   

Abstract

The objective of this study was to investigate the performance of the ViroSeq HIV-1 Genotyping System v2.0 on HIV-1 non-B strains identified in Senegalese patients. The study involved 150 patients, and genotyping was performed using the ViroSeq HIV-1 Genotyping System v2.0 or an in-house method developed by the French National Agency on AIDS Research AC11 when the ViroSeq HIV-1 Genotyping System v2.0 failed. The sequences were edited to assess the performance of sequencing primers at their presumed binding regions. The Polymorphism was studied in the regions between the sequences of Senegalese patients and the subtype B strains used as references. The phylogenetic analysis showed a predominance of CRF02_AG (88/150; 58.7%) and the circulation of 11 subtypes/CRFs, 16 unique recombinant forms (URFs) and one unclassified sample. The amplification and sequencing rates were 98% (147/150) and 96.6% (142/147), respectively. This study showed that only primer B exhibited 100% success, while the failure rate ranged from 1.4% to 71.4% for the other primers (D: 71.4%, A and H: 12.2%, F: 7.5%, G: 5.5% and C: 1.4%). These findings suggest the need for an alternative method or alternative primers for non-B strains that were not sequenced successfully using the ViroSeq HIV-1 Genotyping System v2.0.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23266258     DOI: 10.1016/j.jviromet.2012.11.044

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  7 in total

1.  HIV-1 Drug Resistance Assay Using Ion Torrent Next Generation Sequencing and On-Instrument End-to-End Analysis Software.

Authors:  Michael T Pyne; Keith E Simmon; Melanie A Mallory; Weston C Hymas; Jeffery Stevenson; Adam P Barker; David R Hillyard
Journal:  J Clin Microbiol       Date:  2022-06-14       Impact factor: 11.677

2.  Evaluation of a Novel In-house HIV-1 Genotype Drug Resistance Assay using Clinical Samples in China.

Authors:  Peijie Gao; Fengting Yu; Xiaozhen Yang; Dan Li; Yalun Shi; Yan Wang; Fujie Zhang
Journal:  Curr HIV Res       Date:  2022       Impact factor: 1.341

3.  Molecular epidemiology of HIV-1 in Panama: origin of non-B subtypes in samples collected from 2007 to 2013.

Authors:  Yaxelis Mendoza; Gonzalo Bello; Juan Castillo Mewa; Alexander A Martínez; Claudia González; Claudia García-Morales; Santiago Avila-Ríos; Gustavo Reyes-Terán; Juan M Pascale
Journal:  PLoS One       Date:  2014-01-13       Impact factor: 3.240

4.  Performance of an in-house human immunodeficiency virus type 1 genotyping system for assessment of drug resistance in Cuba.

Authors:  Yoan Alemán; Lore Vinken; Vivian Kourí; Lissette Pérez; Alina Álvarez; Yeissel Abrahantes; Carlos Fonseca; Jorge Pérez; Consuelo Correa; Yudira Soto; Yoeri Schrooten; Anne-Mieke Vandamme; Kristel Van Laethem
Journal:  PLoS One       Date:  2015-02-11       Impact factor: 3.240

5.  Pitfalls of antiretroviral drug resistance genotyping of HIV-1 Group M and Group N from Cameroon by sequenced-based assays.

Authors:  Mohammad-Ali Jenabian; Frédéric Talla; Perrine Talla; François-Xavier Mbopi-Kéou; Charlotte Charpentier; Coumba Toure Kane; Laurent Bélec
Journal:  Niger Med J       Date:  2015 Nov-Dec

6.  PANDAA intentionally violates conventional qPCR design to enable durable, mismatch-agnostic detection of highly polymorphic pathogens.

Authors:  Iain J MacLeod; Christopher F Rowley; M Essex
Journal:  Commun Biol       Date:  2021-02-18

7.  LETTER TO THE EDITOR Performance of the ViroSeq® HIV-1 Genotyping System v2.0 in Central Africa.

Authors:  Linda Chapdeleine Mekue Mouafo; Hélène Péré; Angélique Ndjoyi-Mbiguino; Donato Koyalta; Jean De Dieu Longo; François-Xavier Mbopi-Kéou; Coumba Toure Kane; Laurent Bélec
Journal:  Open AIDS J       Date:  2015-02-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.